CCR2/CCR5抗剂赛尼克里维罗克在实验性结肠炎中减少结肠炎症和纤维化
Xin Song1, Chensheng Jiang2, Mengli Yu2
1Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
塞尼克里维罗克 (CVC) 通过通过CCR5抗作用减少炎症和纤维化,有效治疗结肠炎. 这种药物对炎症性肠病有前途,但不会伤害重要器官.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 塞尼克里维罗克 (CVC) 是一种双重的CCR2/CCR5抗剂,在炎症和纤维状况中已证明有效.
- 结肠炎,以炎症和纤维化为特征,是一个重要的治疗挑战.
研究的目的:
- 评估CVC在治疗大肠炎的实验模型中的疗效.
- 研究CVC在结肠中的抗炎和抗纤维作用背后的机制.
主要方法:
- 利用DSS诱导的急性和慢性结肠炎的小鼠模型.
- 评估疾病活动,组织学变化和炎症和纤维化分子标志物.
- 使用HT29细胞,结肠肌纤维细胞和初级纤维细胞进行了体外研究,以阐明信号通路.
主要成果:
- 在没有器官毒性的急性结肠炎模型中,CVC降低了炎症标志物 (CCL5,TNFα) 和减弱了炎症.
- 在慢性结肠炎模型中,CVC抑制了纤维化标志物 (FN,CTGF,α-SMA,MMP9) 和TGFβ1诱导的激活.
- CVC促进了自,有助于其抗炎作用.
结论:
- 在大肠炎模型中,CVC通过CCL5/CCR5信号显示出显著的抗炎和抗纤维作用.
- CVC是结肠炎症和纤维化的潜在治疗剂,具有良好的安全性.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
